DURHAM – The pharmaceutical company Praetego Inc will use a funding award of $460,000 to advance the company’s research on what it calls its “proprietary small molecules.”
The company noted in a statement that it is committed to improving health outcomes in conditions and diseases driven by Advanced Glycation End-products pathology, with a primary focus on diabetic complications, such as Diabetic Peripheral Neuropathy.
The company, founded in 2017, stated that this award, issued from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) in conjunction with the National Institute of Aging (NIA), will supplement the company’s Phase 2 STTR grant, and expand the company’s collaboration with the University of California at San Diego’s School of Medicine.
According to the company, the funding award offers “a promising opportunity to extend their preclinical investigation of the lead candidate, PTG-630, in preventing progression of neurodegeneration in Alzheimer’s Disease (AD).” The company noted that the work will be done in non-diabetic animal models of Alzheimer’s Disease.
